New venture expands market presence in Spain and Portugal
Verder Scientifi c has announced the opening of Verder Scientifi c Iberia, the company’s 13th local sales offi ce globally. This strategic move enhances its presence in Spain and Portugal, refl ecting a strong commitment to market growth and fostering closer customer relationships in the region. The new offi ce aims to strengthen customer support, expand market coverage, and create synergies across the company’s product lines.
Verder Scientifi c’s brands have already established strong market positions in the Iberian Peninsula, supported by successful collaborations with external distributors. As part of its expansion strategy, Verder Scientifi c Iberia has been formed as a joint venture with Neurtek, a key distributor in the region. Under the leadership of Haritz Elexpuru, Neurtek has been pivotal in promoting brands like QATM, Carbolite Gero, Microtrac, and Eltra. Through this partnership, the Retsch brand, previously managed by distributor Biometa, is now also integrated into the new offi ce.
The new offi ce will directly connect customers with Verder Scientifi c’s offerings, enhancing both accessibility and customer support. Existing contacts within the local team will continue to serve customers, ensuring a seamless transition and continued expertise in the region.
Verder Scientifi c Iberia is based in Eibar and will serve as the central hub for all operations across Spain and Portugal. The new offi ce is equipped with a modern demonstration laboratory and service centre, providing technical support, training, and hands-on experience for customers.
The local team at Verder Scientifi c Iberia will consist of product specialists, service engineers, administrative staff, and marketing professionals, all working together to meet the diverse needs of customers and deliver top- tier support.
The establishment of Verder Scientifi c Iberia marks a signifi cant step in the company’s growth strategy, reinforcing its dedication to expanding its global reach and supporting the largest economies with localised sales teams.
Looking ahead, Verder Scientifi c is excited about the opportunities this new offi ce brings for local customers and its continued growth in the region.
More information online:
ilmt.co/PL/1yNE 64376pr@reply-direct.com
L-R: Dr Jürgen Pankratz (CEO Verder Scientific Division), Haritz Elexpuru (Managing Director Neurtek & Verder Scientific Iberia), Pablo Gardani (Managing Director Market Units).
New collaboration targets precision radiopharmaceuticals
A new partnership between precision medicine specialist Navigo Proteins and Belgian nuclear research centre SCK CEN aims to accelerate development of targeted radiotheranostic treatments using the promising radioisotope terbium-161.
Combining Navigo’s engineered protein platforms with SCK CEN’s radiochemistry and isotope production expertise, the collaboration will explore preclinical applications of Auger-electron emitters for cancer therapy. Unlike conventional treatments, radiotheranostics can deliver radioactive payloads directly to tumour cells, limiting damage to healthy tissue.
“This alliance brings together the right building blocks for next-generation radiopharmaceuticals,” said Dr Ulrich Haupts, CSO and Managing Director at Navigo. “By working with SCK CEN, we gain strategic access to terbium-161 and a wealth of nuclear medicine know-how that can help bring new therapies to the clinic faster.”
Preclinical studies will investigate a series of undisclosed targets with the goal of identifying a lead candidate within the next two to three years. The long-term vision? More personalised, effective, and better-tolerated cancer treatments.
Koen Hasaers, Director of Nuclear Medical Applications at SCK CEN, added: “The synergy between our isotope infrastructure and Navigo’s molecular platforms means faster development timelines – and potentially better outcomes for patients.”
More information online:
ilmt.co/PL/XxlQ 64413pr@reply-direct.com
Jamey Miller.
New leadership to drive LIMS innovation
Confi ence, a leader in Laboratory Information Management System (LIMS) solutions, has announced the appointment of Jamey Miller as its new Chief Product and Technology Offi cer (CPTO). With a strong background in engineering, product management, and operations, Miller brings a wealth of experience
to the company, poised to strengthen Confi ence’s position in the rapidly evolving LIMS market.
Miller’s extensive career includes leadership roles across
engineering, professional services, and operations in both start- ups and large enterprises. His unique blend of skills in scaling technology organisations, driving innovation, and fostering cross- functional collaboration will be pivotal as Confi ence continues to grow its product portfolio and market presence.
“We are thrilled to welcome Jamey to the Confi ence team,” said Patrick Quinlan, CEO of Confi ence. “His technical acumen and leadership will be invaluable as we continue to innovate and expand our eLIMS solutions, ensuring we meet the evolving needs of our customers.”
As CPTO, Miller will oversee the full product development lifecycle, from ideation through to launch and commercialisation. His role will involve guiding teams in product management, engineering, and security, while shaping Confi ence’s long-term strategic vision. Miller’s leadership will be critical in ensuring the successful delivery of new products and the continued success of existing solutions.
“I’m excited to join Confi ence at such a pivotal moment in its growth,” said Miller. “Together with our talented teams, we’ll focus on delivering innovative solutions that address our customers’ challenges and help position Confi ence as a trusted partner in the LIMS space. I look forward to expanding our customer relationships and driving impactful solutions that deliver real value.”
More information online:
ilmt.co/PL/o2NB 64420pr@reply-direct.com
Strategic acquisition expands US presence
Clean Cells, part of the Clean Biologics group and a leader in biopharmaceutical quality control services, has announced the strategic acquisition of Karyologic Inc., a specialised karyotyping services company based in Durham, North Carolina. This move marks a signifi cant step in Clean Cells’ global growth strategy, establishing a direct operational presence in the US.
Karyologic, a trusted provider of cytogenetic testing services essential for biologics development and cell therapy products, will now enable Clean Cells to offer enhanced karyotype services to its North American clients. This acquisition strengthens the company’s ability to bring its full range of services closer to US-based customers.
Joseph Jammal, CEO of Clean Cells, shared his excitement about the acquisition: “This milestone allows us to expand our operational footprint in the US, supporting our mission to drive innovation in biologics through exceptional service across Europe and North America.”
Elizabeth Gonzalez, CEO of Karyologic, expressed optimism about the future: “By joining forces with Clean Cells, we can combine our cytogenetic expertise with their comprehensive biologics services. This partnership will enhance the value and reliability we provide to clients globally.”
Denis Ribon, managing partner at ARCHIMED, Clean Cells’ majority
investor, also welcomed the move: “This acquisition is a key step in our strategy to expand Clean Cells’ international presence and strengthen its position in the fast-growing biologics market.”
The acquisition, finalised on 31 March 2025, kicks off a series of integration activities designed to utilise the combined strengths of both companies, enhancing service delivery and client support.
More information online:
ilmt.co/PL/KmR9 64425pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
